ABOUT
Jimmi Hatton - Pharm.D., FCCP, FCCM, CCRC
Dr. Hatton's primary research focus area is critical care therapeutics and nutrition, specifically applied to the neurotrauma population. Since 1991 she has been a co-investigator in Phase II and Phase III clinical trials of drugs under investigation for treatment of traumatic brain injury. She has been a co-investigator of the clinical project in an NIH-funded, five-year program project grant evaluating mechanisms of brain injury and the systemic metabolic response. Her research focus is expanding to include analytical techniques and translational research in designing optimal dosing strategies for drugs with potential application in the traumatic brain injured patient. In 2005, Dr. Hatton joined Dr. Ed Hall at the Spinal Cord and Brain Injury Research Center as a collaborator in translational pharmacokinetic/pharmacodynamic investigations in traumatic brain injury. In 2006, her experience in clinical research and teaching of clinical research ethics will be utilized in a Department Scholarship and Mentoring enhancement program for faculty, professional and graduate student development.
Selected Publications/Presentations
- Zarbock SD, Steinke D, Hatton J, Magnuson B, Smith KM, Cook AM. Successful Enteral Nutritional Support in the Neurocritical Care Unit. Neurocritical Care, accepted June 2008.
- Hatton J, Empey P, Rosbolt B, Jackson T, Kryscio R, Young B. Dosing and Safety of Cyclosporine in Patients with Severe Brain Injury. JNeurosurg, in press November 2008.
- Hatton,J, Young B. JNS Letter to editor; reply to JNS 2006, 105:343-852 article. JNeurosurg 2007 May; 106(5).
- Hatton J, Kryscio R, Ott L, Young B. Systemic metabolic effects of insulin-like growth factor—1 and growth hormone therapy in patients with acute traumatic brain injury/ JNeurosurg 2006 Dec;105: 843-852.
- Empey Philip, McNamara P, Young B, Rosbolt MB, Hatton J. Cyclosporin A Disposition following acute traumatic brain injury. J Neurotrauma 2006 Jan; 23(1):109-16.
- Cook, AM, Hatton J. “Neurological Impairment" In American Society of Parenteral and Enteral Nutrition Adult Nutrition Support Science and Practice: An Interdisciplinary Core Curriculum, November 2007: 424-439.
- PSmith KM, Jeske CS, Young B, Hatton J. Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. Neurosurgery 2006 Mar; 58(3):426-33.
- ACCP Spring Practice and Research Forum "Developing Advanced Research Skills for Graduate Training and Competitive Funding" Myrtle Beach, SC 2005
- Hatton J, Empey P, Young B, McNamara P. Pharmacokinetic Modeling of CsA in TBI Patients. JNT Oct 2005 (abstract).
- ACCP Spring Practice and Research Forum "Research Project Development in the Clinical Setting"; Myrtle Beach, SC. 2005
- Hatton J, Rosbolt MB,Young B. Cyclosporin Safety in Adult Patients with Severe Traumatic Brain Injury. JNS, May 2004.
- Rosbolt, MB, Hatton, J. "Disease Specific: Head and Spinal Injury" In Clinical Nutrition:Enteral and Tube Feeding;4th edition. Rolandelli RH ed. 2004.
- Green A, Banks S, Jay M, Hatton J. Stability of Nimodipine Stored in Oral Dosing Syringes, American Journal of Health Systems Pharmacists, 2004; 61 :493-6.
- ACCP Annual Meeting: Debate: Do Placebo Groups Have a Role in Clinical Trials? Pro: Placebo Groups Should be Included in Clinical Trials; Dallas TX 2004
- AANS 72nd Annual Meeting " Cyclosporin Safety in Adult Patients with Severe TBI", Orlando, FL 2004
- Varney KL, Young B, Hatton J. Albumin Use in Neurosurgical Critical Care. Pharmacotherapy, 2003; 23(1) 88-92.
- Hatton J. Pharmacological Treatment of Traumatic Brain Injury: A Review of Agents in Development. CNS Drugs, 2001;15(7):553-581.
Selected Grants
- The Effect of Cyclosporine on Isoprostane and Neuroprostane Production Following Severe Traumatic Brain Injury- Kentucky Spinal Cord and Head Injury Research Trust - January 2005-January 2007 (PI Jimmi Hatton; CoPI Byron Young)
- Career Training in Therapeutics and Translational Research - NIH CRCA OD-00-002 $1,058,896. May 2003-August 2005. (PI Steve Shedlofsky; CoPI Jimmi Hatton, 25%)
- The effect of TBI on Gene Expression Profile and Drug Disposition - A Pilot Study DNA Micro Assay Facility Research Fund $5,000 (PI - Jimmi Hatton 5%) November 2002 - June 2003.
- Developing Treatment Models of Traumatic Brain Injury - UKCMC Research Fund $15,000 (PI Jimmi Hatton 20%) July 2002-June 2003
- Intravenous Cyclosporin in the Treatment of Traumatic Brain Injury - A Pilot Dose - Finding Study. NIH $947,410. (PI - Byron Young; CoPI - Jimmi Hatton 15%). March 2001 - 2005.
- Effect of Cyclosporin A on markers of secondary injury following severe head trauma. Kentucky Spinal Cord and Head Injury Research Board. $298,528 (PI - Byron Young; CoPI - Jimmi Hatton 15%). January 2000 - January 2004.
- Nutrient Modulation of the Metabolic Response Following Pediatric Head Injury. Kentucky Spinal Cord and Health Injury Research Institute. $300,000. (Principal Investigator 10%). February 1, 1997 - January 31, 2003.